Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome
Endocrinology and Metabolism
;
: 120-126, 2016.
Article
in English
| WPRIM
| ID: wpr-186221
ABSTRACT
BACKGROUND:
Apolipoprotein (Apo) B-48 is an intestinally derived lipoprotein that is expected to be a marker for cardiovascular disease (CVD). Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a vascular-specific inflammatory marker and important risk predictor of CVD. The aim of this study was to explore the effect of pitavastatin treatment and life style modification (LSM) on ApoB-48 and Lp-PLA2 levels in metabolic syndrome (MS) patients at relatively low risk for CVD, as a sub-analysis of a previous multi-center prospective study.METHODS:
We enrolled 75 patients with MS from the PROPIT study and randomized them into two treatment groups 2 mg pitavastatin daily+intensive LSM or intensive LSM only. We measured the change of lipid profiles, ApoB-48 and Lp-PLA2 for 48 weeks.RESULTS:
Total cholesterol, low density lipoprotein cholesterol, non-high density lipoprotein cholesterol, and ApoB-100/A1 ratio were significantly improved in the pitavastatin+LSM group compared to the LSM only group (P≤0.001). Pitavastatin+LSM did not change the level of ApoB-48 in subjects overall, but the level of ApoB-48 was significantly lower in the higher mean baseline value group of ApoB-48. The change in Lp-PLA2 was not significant after intervention in either group after treatment with pitavastatin for 1 year.CONCLUSION:
Pitavastatin treatment and LSM significantly improved lipid profiles, ApoB-100/A1 ratio, and reduced ApoB-48 levels in the higher mean baseline value group of ApoB-48, but did not significantly alter the Lp-PLA2 levels.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Apolipoproteins
/
Cardiovascular Diseases
/
Cholesterol
/
Prospective Studies
/
1-Alkyl-2-acetylglycerophosphocholine Esterase
/
Apolipoprotein B-48
/
Life Style
/
Lipoproteins
/
Cholesterol, LDL
Type of study:
Controlled clinical trial
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Endocrinology and Metabolism
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS